Cyclacel Pharmaceuticals Faces Nasdaq Delisting
Ticker: BGMSP · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1130166
Sentiment: bearish
Topics: delisting, nasdaq, compliance
Related Tickers: CYCC
TL;DR
Nasdaq's kicking Cyclacel off the exchange Friday, stock's done.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed an 8-K on October 24, 2024, reporting a notice of delisting or failure to meet continued listing standards. The company's common stock was previously suspended from trading on The Nasdaq Capital Market, and it is anticipated that the delisting will become effective on October 25, 2024.
Why It Matters
This filing indicates that Cyclacel Pharmaceuticals' stock will no longer be traded on the Nasdaq, significantly impacting liquidity and investor access.
Risk Assessment
Risk Level: high — The company is facing delisting from a major stock exchange, indicating severe financial distress or non-compliance with listing requirements.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- Nasdaq Capital Market (company) — Stock Exchange
- October 25, 2024 (date) — Effective date of delisting
- October 22, 2024 (date) — Earliest event reported
- October 24, 2024 (date) — Filing date
FAQ
What is the primary reason for Cyclacel Pharmaceuticals' notice of delisting?
The filing indicates a notice of delisting or failure to satisfy a continued listing rule or standard by The Nasdaq Capital Market.
When is the delisting from The Nasdaq Capital Market expected to become effective?
The delisting is anticipated to become effective on October 25, 2024.
What was the date of the earliest event reported in this 8-K filing?
The earliest event reported was on October 22, 2024.
What is the filing date of this 8-K report?
This 8-K report was filed on October 24, 2024.
What is the former name of Cyclacel Pharmaceuticals, Inc.?
The former name of Cyclacel Pharmaceuticals, Inc. was XCYTE THERAPIES INC.
Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-10-24 16:00:20
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital Ma
Filing Documents
- tm2426738d1_8k.htm (8-K) — 27KB
- tm2426738d1_ex99-1.htm (EX-99.1) — 11KB
- tm2426738d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- tm2426738d1_ex99-1img002.jpg (GRAPHIC) — 3KB
- 0001104659-24-111145.txt ( ) — 266KB
- cycc-20241022.xsd (EX-101.SCH) — 3KB
- cycc-20241022_def.xml (EX-101.DEF) — 26KB
- cycc-20241022_lab.xml (EX-101.LAB) — 36KB
- cycc-20241022_pre.xml (EX-101.PRE) — 25KB
- tm2426738d1_8k_htm.xml (XML) — 5KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Cyclacel Pharmaceuticals, Inc., dated October 24, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYCLACEL PHARMACEUTICALS, INC. By: /s/ Paul McBarron Name: Paul McBarron Title: Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer Date: October 24, 2024